A startup company, Pelage Pharmaceuticals, will develop the drug discovered by the three professors.
As a leader in the global movement toward open access to publicly funded research, the University of California is taking a firm stand by deciding not to renew its subscriptions with Elsevier.
The financial support comes from a $22 million investment in the University of California from a state law that promotes innovation and entrepreneurship.
A study by the Bay Area Council Economic Institute of the rapid formation of startups at UC campuses found that universitywide research has led to hundreds of new companies, supporting 146,000 jobs.
Because of the pioneering work of Dr. Donald Kohn, a researcher with UCLA's Broad Stem Cell Research Center, the potential to bring stem cell therapies to patients is now a reality.
In the past six years, more than 140 startup companies have been formed based on UCLA research discoveries, including 27 that were launched in the fiscal year ending in June 2015.
The campus will use its share of the proceeds to support research programs aimed at generating new discoveries that serve the public good, and to support scholarships and fellowships.
Using a tumor rejection antigen to identify stem cells could help ensure stem cell research studies are accurate.
Company emerges from King Abdulaziz City for Science and Technology and the UCLA Center for Excellence in Green Technology. It aims to revolutionize electronics by using carbon-based nanomaterials to lower power consumption and improve performance of smartphones and wearable devices.
The Westwood Technology Transfer will focus on better protecting and optimizing the discoveries and inventions developed through campus research.
UCLA inventors recently presented their innovative research at UC’s annual Technology Commercialization Forum held recently in San Francisco.
Opinion: How a terrible Supreme Court decision about player pianos created the cover song and laid a foundation for creativity.
Flexible smartphone screens, room-illuminating curtains and nanodiamonds that deliver chemotherapy directly into tumors are among the innovations resulting from the joint work of UCLA and private industry.
The UCLA Specialized Program of Research Excellence team is a multidisciplinary group of scientists striving to find a cure for a cancer that will affect roughly one in six men.
A new entrepreneur-in-residence program (EIR) launched at UCLA this month comes to the aid of campus inventors by bringing in experienced entrepreneurs to provide guidance and advice.